JOANN Inc. (Nasdaq: JOAN) announced its financial results for the first quarter of fiscal year 2024, revealing an adjusted loss of $0.93 per share, which was far worse than the consensus estimate for a loss of $0.66 per share. 

When considering the full year outlook, the company is projecting a potential decline in topline sales ranging from 1% to 4% for fiscal year 2024. 

In after-hours, $JOAN was trading at $1.50, representing a decrease of $0.11 or 6.83%.

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company focused on developing targeted antibody-drug conjugates for the treatment of cancer, received a price target increase from $15 to $19 by Canaccord Genuity. 

With a closing price of $15.37 on Monday, this upward revision suggests a potential upside of $3.63 (+23.64%) for $IMGN, based on Canaccord Genuity's analysis.

Interactive Brokers Group, Inc. (Nasdaq: IBKR), a leading brokerage firm providing electronic trading platforms and services for individual and institutional clients, had its price target raised from $104 to $106 by Jefferies. 

Despite $IBKR closing at $80.44 on Monday, this adjusted price target indicates a potential upside of $25.56 (+31.78%) according to Jefferies' view.

TransUnion (NYSE: TRU), a global information and insights company that provides credit and marketing services, received a price target increase from $71 to $80 by Goldman Sachs. 

With a closing price of $73.14 on Monday, this revised price target suggests a potential upside of $6.86 (+9.39%) for $TRU, based on Goldman Sachs' analysis.

It is worth noting that the potential upsides mentioned above are derived from the assessments of various brokerage firms or analysts. These estimates provide informative viewpoints within the investment landscape, but it is crucial for investors to consider them in conjunction with market dynamics and their individual investment strategies.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)